Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent

Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent

Abstract Folate receptor (FR)-targeted small molecule drug conjugates (SMDCs) have shown promising results in early stage clinical trials with microtubule destabilizing agents, such as vintafolide and EC1456. In our effort to develop FR-targeted SMDCs with varying mechanisms of action, we synthesize...

Full description

Bibliographic Details
Main Authors: Joseph A. Reddy, Melissa Nelson, Christina Dircksen, Marilynn Vetzel, Theresa Johnson, Vicky Cross, Elaine Westrick, LongWu Qi, Spencer Hahn, Hari Krishna Santhapuram, Garth Parham, Kevin Wang, Jeremy F. Vaughn, Albert Felten, Michael Pugh, June Lu, Patrick Klein, Iontcho R. Vlahov, Christopher P. Leamon
Format: Article
Language:English
Published: Nature Portfolio 2020-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-020-69682-9

Internet

https://doi.org/10.1038/s41598-020-69682-9

Similar Items